Group B meningococcal vaccine science and policy
Capsular group B Neisseria meningitidis is one of the leading causes of death in developed countries. A new vaccine (4CMenB) has recently been developed which was found to have an acceptable safety profile in clinical studies and to be immunogenic. This review examines the evidence supporting the li...
| 主要な著者: | , |
|---|---|
| フォーマット: | Journal article |
| 言語: | English |
| 出版事項: |
Elsevier
2015
|